{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04340609",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CT/AMI/01/2019"
      },
      "Organization": {
        "OrgFullName": "PT. Prodia Stem Cell Indonesia",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Stem Cell in Acute Myocardial Infarction",
      "OfficialTitle": "Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Acute Myocardial Infarction",
      "Acronym": "AMI"
    },
    "StatusModule": {
      "StatusVerifiedDate": "April 2020",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 11, 2019",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 11, 2020",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 11, 2021",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "February 8, 2020",
      "StudyFirstSubmitQCDate": "April 7, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "April 9, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "June 3, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "June 4, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "PT. Prodia Stem Cell Indonesia",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No",
      "IsUSExport": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The study will perform UC-MSCs transplantation in 2 groups and 1 control group with standard treatment. Each group consists of 5 subjects. In the first group UC-MSCs will be transplanted via intravenous (IV) route and the second group via intracoronary (IC) route. The IV group will receive 2 million cells/kg for each subject and the dosage of IC group is 50 million cells for each subject. All groups will be observed until 1 year."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Acute Myocardial Infarction"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Allogeneic Mesenchymal Stem Cells",
          "Umbilical Cord Mesenchymal Stem Cells",
          "Intravenous Mesenchymal Stem Cells",
          "Intracoronary Mesenechymal Stem Cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "15",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Intravenous Group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Dosage of intravenous route is 2 million MSCs/kg for each subject.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mesenchymal Stem Cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Intracoronary Group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Dosage of intracoronary route is Â±50 million MSCs for each subject.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mesenchymal Stem Cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Control Group",
            "ArmGroupType": "No Intervention",
            "ArmGroupDescription": "Standard treatment of acute myocardia infarction"
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Mesenchymal Stem Cells",
            "InterventionDescription": "The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Intracoronary Group",
                "Intravenous Group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Major adverse cardiac events (MACE) endpoints of mortality",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "2 weeks after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Major adverse cardiac events (MACE) endpoints of mortality",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "3 months after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Major adverse cardiac events (MACE) endpoints of mortality",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "6 months after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Major adverse cardiac events (MACE) endpoints of mortality",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "12 months after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Re-infarction",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "2 weeks after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Re-infarction",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "3 months after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Re-infarction",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "6 months after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Re-infarction",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "12 months after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Target vessel revascularization (TVR)",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "2 weeks after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Target vessel revascularization (TVR)",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "3 months after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Target vessel revascularization (TVR)",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "6 months after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Target vessel revascularization (TVR)",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "12 months after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Heart failure hospitalization",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "2 weeks after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Heart failure hospitalization",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "3 months after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Heart failure hospitalization",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "6 months after stem cell"
          },
          {
            "PrimaryOutcomeMeasure": "Heart failure hospitalization",
            "PrimaryOutcomeDescription": "To assess the safety of using allogeneic UC-MSCs therapy for acute myocardial infarction.",
            "PrimaryOutcomeTimeFrame": "12 months after stem cell"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Cardiac MRI",
            "SecondaryOutcomeDescription": "a test to see improvement in LVEF(%), improvement in regional function, improvement in perfusion, reduction of infarct size.",
            "SecondaryOutcomeTimeFrame": "6 months after stem cell"
          },
          {
            "SecondaryOutcomeMeasure": "Cardiac MRI",
            "SecondaryOutcomeDescription": "a test to see improvement in LVEF (%), improvement in regional function, improvement in perfusion, reduction of infarct size.",
            "SecondaryOutcomeTimeFrame": "12 months after stem cell"
          },
          {
            "SecondaryOutcomeMeasure": "Echocardiography",
            "SecondaryOutcomeDescription": "Left ventricular volumes will be determined at end-diastole and end-systole by quantitative biplane assessment. Endocardial borders will be manually traced from apical four-chamber and two-chamber views. Left ventricular volumes will be used to calculate ejection fraction using the biplane modified Simpson's summation-of-disks method recommended by the American Society of Echocardiography.",
            "SecondaryOutcomeTimeFrame": "6 months after stem cell"
          },
          {
            "SecondaryOutcomeMeasure": "Echocardiography",
            "SecondaryOutcomeDescription": "Left ventricular volumes will be determined at end-diastole and end-systole by quantitative biplane assessment. Endocardial borders will be manually traced from apical four-chamber and two-chamber views. Left ventricular volumes will be used to calculate ejection fraction using the biplane modified Simpson's summation-of-disks method recommended by the American Society of Echocardiography.",
            "SecondaryOutcomeTimeFrame": "12 months after stem cell"
          },
          {
            "SecondaryOutcomeMeasure": "Electrocardiography (ECG)",
            "SecondaryOutcomeDescription": "to detects cardiac (heart) abnormalities by measuring the electrical activity generated by the heart as it contracts",
            "SecondaryOutcomeTimeFrame": "3 months after stem cell"
          },
          {
            "SecondaryOutcomeMeasure": "Electrocardiography (ECG)",
            "SecondaryOutcomeDescription": "to detects cardiac (heart) abnormalities by measuring the electrical activity generated by the heart as it contracts",
            "SecondaryOutcomeTimeFrame": "6 months after stem cell"
          },
          {
            "SecondaryOutcomeMeasure": "Electrocardiography (ECG)",
            "SecondaryOutcomeDescription": "to detects cardiac (heart) abnormalities by measuring the electrical activity generated by the heart as it contracts",
            "SecondaryOutcomeTimeFrame": "12 months after stem cell"
          },
          {
            "SecondaryOutcomeMeasure": "Wellness Parameter",
            "SecondaryOutcomeDescription": "hs-CRP, antioxidant, IL-6, IL-10, PA1, Fibrinogen",
            "SecondaryOutcomeTimeFrame": "6 months after stem cell"
          },
          {
            "SecondaryOutcomeMeasure": "Laboratory Assessment",
            "SecondaryOutcomeDescription": "Haematology, Serum Chemistry, Cardiac Biomarker",
            "SecondaryOutcomeTimeFrame": "12 months after stem cell"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nSTEMI patients within 5 days after symptom onset of a first ST-segment elevation myocardial infarction\nHave undergone successful percutaneous coronary intervention (PCI) with drug eluting stent implantation of the infarct-related artery and demonstrated hypokinesia or akinesia that involved more than two thirds of the LV anteroseptal, lateral, or inferior wall with LV ejection fraction of < 45% by echocardiography.\nAbility to understand and provide signed informed consent, or have a designated legal guardian or spouse legally able and willing to make such decisions on the subject's behalf,\nWillingness to attend all scheduled safety follow-up visits\nSubjects need to have a specific criteria of having a single vessel disease (ostial or proximal LAD vessels) that caused extensive anterior infarction (EF <45).\n\nExclusion Criteria:\n\nHemodynamic instability as demonstrated by any of the following,\nRequirement of intra-aortic balloon pump of left ventricular assist device,\nNeed for inotropic support (e.g. dopamine and/or dobutamine) for more than 36 hours for the maintenance of mean arterial blood pressure â¥ 60 mmHg,\nPrevious or current concomitant serious illnesses, such as cancer, hematological disorders (Hb < 10 g/dL, WBC < 4 or > 11x109/L, or platelets < 100x109/L), kidney failure (creatinine level > 2.5 mg/dL, or creatinine clearance < 30 cc/min), serious infection or any other co-morbidities that could impact patient's short-term survival, psychiatric illness, history of drug of alcohol abuse,\nProsthetic valves,\nHypertrophic or restrictive cardiomyopathy,\nWomen of child-bearing potential,\nInability to comply with the protocol,\nCurrently using implantable electronic defibrillator or pacemaker",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "30 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Teguh Santoso, Professor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "088293176579",
            "CentralContactEMail": "profteguhsantosos@gmail.com"
          },
          {
            "CentralContactName": "Cynthia Retna Sartika, Dr",
            "CentralContactRole": "Contact",
            "CentralContactEMail": "c.sartika@gmail.com"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "PT Prodia StemCell Indonesia",
            "LocationStatus": "Recruiting",
            "LocationCity": "Jakarta",
            "LocationCountry": "Indonesia"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009203",
            "ConditionMeshTerm": "Myocardial Infarction"
          },
          {
            "ConditionMeshId": "D000007238",
            "ConditionMeshTerm": "Infarction"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007511",
            "ConditionAncestorTerm": "Ischemia"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000009336",
            "ConditionAncestorTerm": "Necrosis"
          },
          {
            "ConditionAncestorId": "D000017202",
            "ConditionAncestorTerm": "Myocardial Ischemia"
          },
          {
            "ConditionAncestorId": "D000006331",
            "ConditionAncestorTerm": "Heart Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11307",
            "ConditionBrowseLeafName": "Myocardial Infarction",
            "ConditionBrowseLeafAsFound": "Myocardial Infarction",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9434",
            "ConditionBrowseLeafName": "Infarction",
            "ConditionBrowseLeafAsFound": "Infarction",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9695",
            "ConditionBrowseLeafName": "Ischemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11436",
            "ConditionBrowseLeafName": "Necrosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5698",
            "ConditionBrowseLeafName": "Coronary Artery Disease",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18658",
            "ConditionBrowseLeafName": "Myocardial Ischemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8571",
            "ConditionBrowseLeafName": "Heart Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}